Reporting from the ESMO Virtual Congress 2020, Joseph Gligorov features important findings from TNBC studies elaborating advances of neoadjuvant immunotherapy in early-stage disease, and testing first-line immunotherapy in the metastatic setting.
Besides covering Impassion 031 in early TNBC, he discusses also the results from the IMpassion130 and IMpassion131 trials in unresectable locally advanced or metastatic disease, which proved to be very different despite an apparently similar study design.
Abstracts:
- LBA11 - IMpassion031: results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Simultaneous publication: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31953-X/fulltext - LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
- LBA16 - IMpassion130: final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in patients with previously untreated locally advanced or metastatic triple-negative breast cancer
This video was supported with grants from Daiichi Sankyo, Novartis and Roche